Amicus Therapeutics (FOLD) Prelim. FY Revenue Tops Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. TMUS
9. SPY
10. SBUX

Go back to Amicus Therapeutics (FOLD) Prelim. FY Revenue Tops Consensus

Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook

January 9, 2023 7:00 AM EST

Significant Growth in Demand with More Than 2,000 People Living with Fabry Disease on Galafold by End of 2022

2022 Full Year Revenue of ~$329M, Representing 16% YoY Growth at CER

Continued Double-Digit Growth in Galafold Revenue of 12-17% at CER Expected in 2023

Multiple Approvals and Launches Expected in 2023 for AT-GAA in Pompe Disease

On-Track to Achieve non-GAAP Profitability in 2H2023

PHILADELPHIA, Jan. 09, 2023 (GLOBE NEWSWIRE) --... More